Biogen (BIIB) in Autoimmune Disease Deal Worth Up To $544M

Biogen (BIIB – Analyst Report) has signed up with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the latter's MT-1303, an oral compound that targets the S1P receptor. Biogen will get worldwide (excluding Asia) rights

Leave a Reply

Your email address will not be published. Required fields are marked *

Please solve the math to submit *